Indications |
Oral Schizophrenia Adult: Initially, 6 mg once daily in the morning. May increase dose in multiples of 3 mg at intervals of >5 days. Max: 12 mg daily.
|
||||||
Contraindications |
Hypersensitivity to paliperidone or risperidone. | ||||||
Warnings / Precautions |
Not to be used in elderly patients with dementia-related psychosis due to increased risk of mortality. Avoid use in patients with congenital long-QT syndrome or history of cardiac arrhythmia. May cause oesophageal dysmotility and aspiration; caution in patients at risk of pneumonia. Increased risk of tardive dyskinesia in the elderly, especially women. Monitor glucose control in patients with or with risk factors for diabetes or other disorders of glucose regulation. Monitor for mental status changes, fever, muscle rigidity and/or autonomic instability. May cause orthostatic hypotension, impaired core body temperature, significant wt gain and/or sedation. Monitor for behaviour changes or suicidal ideation. Patients with breast cancer or other prolactin-dependent tumors, renal impairment or at risk of seizures. May mask toxicity of other drugs or conditions e.g. intestinal obstruction, Reye's syndrome, brain tumor. Safety and efficacy have not been established in children <18 yr. | ||||||
Adverse Reactions |
Tachycardia, headache, somnolence, orthostatic hypotension, AV block, bundle branch block, akathisia, parkinsonism, dizziness, wt gain, hyperkinesia, dose-dependent dyskinesia, tremor, weakness, abdominal pain, dry mouth, hypersalivation, vomiting. | ||||||
Overdose Reactions |
Symptoms: Extrapyramidal symptoms, gait unsteadiness, drowsiness and sedation, tachycardia and hypotension, and QT prolongation. Treatment is supportive. Monitor closely until patient recovers. | ||||||
Drug Interactions |
Increased risk of antipsychotic-related extrapyramidal symptoms when used with central acetylcholinesterase inhibitors. May reduce the therapeutic effect of anti-Parkinson's agents (dopamine agonist). Serum levels may be reduced by carbamazepine. Concurrent use may increase toxicity of other CNS depressants. Serum levels may be increased by itraconazole. Lithium may increase neurotoxic effects of paliperidone. See Below for More paliperidone Drug Interactions |
||||||
Food Interactions |
Avoid concurrent use with kava kava, gotu kola, valerian, St John's wort. | ||||||
Mechanism of Actions |
Paliperidone is a benzisoxazole atypical antipsychotic which is a main active metabolite of risperidone. It is reported to be an antagonist at dopamine D2, serotonin (5-HT2), adrenergic (a1 and a2), and histamine (H1) receptors. It is used for the acute and maintenance treatment of schizophrenia. Absorption: Bioavailability: About 28%. Distribution: Protein binding: 74%. Metabolism: Hepatic via CYP2D6 and 3A4. Excretion: Elimination half-life: 23 hr; prolonged in renal impairment. Excreted in urine (80%) and faeces (11%). |
||||||
Administration |
May be taken with or without food. (Take consistently either always w/ or always w/o food. Swallow whole, do not divide/chew/crush.) |
||||||
Storage Conditions |
Oral: Store up to 25°C. | ||||||
ATC Classification |
N05AX13 - paliperidone ; Belongs to the class of other antipsychotics. | ||||||
Storage |
Oral: Store up to 25°C. | ||||||
Available As |
|
Paliperidone
Post Review about Paliperidone Click here to cancel reply.
Paliperidone Containing Brands
Paliperidone is used in following diseases
Drug - Drug Interactions of Paliperidone
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.